Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Return on Capital Employed: 2016-2020

Historic Return on Capital Employed for Outlook Therapeutics (OTLK) over the last 4 years, with Jun 2020 value amounting to -12.15%.

  • Outlook Therapeutics' Return on Capital Employed rose 609.00% to -12.15% in Q2 2020 from the same period last year, while for Jun 2020 it was -12.15%, marking a year-over-year increase of 609.00%. This contributed to the annual value of 62.48% for FY2019, which is 5967.00% up from last year.
  • According to the latest figures from Q2 2020, Outlook Therapeutics' Return on Capital Employed is -12.15%, which was down 534.75% from 2.79% recorded in Q1 2020.
  • Outlook Therapeutics' Return on Capital Employed's 5-year high stood at 15.18% during Q2 2018, with a 5-year trough of -18.24% in Q2 2019.
  • For the 3-year period, Outlook Therapeutics' Return on Capital Employed averaged around 1.44%, with its median value being 4.69% (2018).
  • Per our database at Business Quant, Outlook Therapeutics' Return on Capital Employed skyrocketed by 1,322bps in 2018 and then tumbled by 3,341bps in 2019.
  • Quarterly analysis of 5 years shows Outlook Therapeutics' Return on Capital Employed stood at 5.73% in 2016, then plummeted by 120bps to 4.53% in 2017, then skyrocketed by 69bps to 5.22% in 2018, then climbed by 20bps to 5.41% in 2019, then spiked by 609bps to -12.15% in 2020.
  • Its last three reported values are -12.15% in Q2 2020, 2.79% for Q1 2020, and 5.41% during Q4 2019.